Companies · Biotechnology
COLLEGE STATION · Biotechnology
Diligence memoA one-page analyst read on G-Con Manufacturing, Inc. — recommendation, valuation, rhythm, risks.→G-Con Manufacturing, Inc. looks fair against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
G-Con Manufacturing, Inc. is one of 4293 Biotechnology companies tracked from COLLEGE STATION. By capital raised it ranks mid-pack (ahead of 61% of sector peers), and in the upper tier by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.
Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 61% of sector peers (real $). Modeled value above 71% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #105 of 216.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| TRACT Therapeutics, Inc. | Series A | $15.0M | $542.3M | 3.00× |
| TechAccel, LLC | Series A | $15.0M | $542.3M | 3.00× |
| Arrakis Therapeutics, Inc. | Series A | $28.2M | $542.3M | 3.00× |
| Trident Labs, Inc. | Series A | $14.0M | $506.1M | 2.80× |
| Meissa Vaccines Inc | Series A | $15.2M | $503.1M | 2.78× |
| Vibe Bioscience Ltd. | Series A | $13.9M | $501.1M | 2.77× |
| Trovagene, Inc. | Series A | $45.3M | $488.0M | 2.70× |
| Taiga Biotechnologies, Inc. | Series A | $37.9M | $485.3M | 2.68× |
| Equinox, Inc. | Series A | $34.7M | $485.2M | 2.68× |
| Aruna Biomedical Inc | Series A | $22.4M | $480.5M | 2.66× |
| Vibe Bioscience Corp | Series A | $13.7M | $476.8M | 2.64× |
| Adarza BioSystems, Inc. | Series A | $31.5M | $461.9M | 2.56× |
| G-Con Manufacturing, Inc. this company | Series A | $13.0M | $180.8M | 1.00× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series A | $5.0M | 2014-06-09 | $22.7M | $180.8M | 85% |
| Series A | $3.0M | 2018-03-13 | $13.6M | $108.5M | 90% |
| Series A | $5.0M | 2019-05-15 | $22.7M | $180.8M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| David Shanahan | — | 2 other | 2019-05 |
| David M. Shanahan | — | 1 other | 2014-06 |
| Robert P. Landin | — | 1 other | 2014-06 |
| Lloyd P Thompson | — | — | 2019-05 |
| Maik Jornitz | — | — | 2018-03 |
| Maik P. Jornitz | — | — | 2014-06 |
| Melissa P. Hall | — | — | 2018-03 |
| Paul P Moore | — | — | 2019-05 |
| Robert P. Williams | — | — | 2018-03 |
| Sidney P. Backstrom | — | — | 2018-03 |
| Thomas P. Lyles | — | — | 2018-03 |
| William P Burkoth | — | — | 2018-03 |
G-Con Manufacturing, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Gradalis, Inc. | Biotechnology | Series C | $56.7M | $79.7M | network3 shared operators · same sector |
| EnGeneIC Ltd. (ABN: 59 091 336 499) | Biotechnology | Series A | $13.0M | $144.6M | same sector · same stage |
| Cerium Pharmaceuticals, Inc. | Biotechnology | Series A | $13.1M | $193.4M | same sector · same stage |
| Gemin X Pharmaceuticals Inc | Biotechnology | Series A | $13.2M | $141.6M | same sector · same stage |
| Cellinfinity Bio Holding Company, LLC | Biotechnology | Series A | $13.2M | $216.2M | same sector · same stage |
| Tissue Regeneration Systems Inc | Biotechnology | Series A | $13.2M | $148.0M | same sector · same stage |
| Insilico Medicine, Inc. | Biotechnology | Series A | $12.8M | $216.9M | same sector · same stage |
| Arcturus Therapeutics, Inc. | Biotechnology | Series A | $13.3M | $214.2M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| GPB Scientific, LLC | Biotechnology | Series B | $59.6M | 88% |
| GlycosBio Inc. | Biotechnology | Series A | $6.9M | 88% |
| Globin Solutions, Inc. | Biotechnology | Series A | $162.7M | 88% |
| Glycomine, Inc. | Biotechnology | Series A | $178.4M | 87% |
| Gnosko Bio Inc. | Biotechnology | Pre-Seed | $512K | 87% |
| G.I. Windows, Inc. | Biotechnology | Series B | $218.3M | 86% |
| Gliacure, Inc. | Biotechnology | Series A | $57.0M | 86% |
| GRI Bio, Inc. | Biotechnology | Series B | $4.8M | 86% |
See where G-Con Manufacturing, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at G-Con Manufacturing, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.